Dr Reddy's Laboratories Cash Flow from Operating Activities 2012-2026 | RDY
Dr Reddy's Laboratories annual/quarterly cash flow from operating activities history and growth rate from 2012 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Dr Reddy's Laboratories cash flow from operating activities for the quarter ending March 31, 2026 was $607M, a 11.38% increase year-over-year.
- Dr Reddy's Laboratories cash flow from operating activities for the twelve months ending March 31, 2026 was $1.576B, a 36.92% increase year-over-year.
- Dr Reddy's Laboratories annual cash flow from operating activities for 2025 was $0.545B, a 0% decline from 2024.
- Dr Reddy's Laboratories annual cash flow from operating activities for 2024 was $0.545B, a 23.88% decline from 2023.
- Dr Reddy's Laboratories annual cash flow from operating activities for 2023 was $0.716B, a 93.51% increase from 2022.
|
Dr Reddy's Laboratories Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $545 |
| 2024 | $545 |
| 2023 | $716 |
| 2022 | $370 |
| 2021 | $488 |
| 2020 | $396 |
| 2019 | $415 |
| 2018 | $277 |
| 2017 | $332 |
| 2016 | $623 |
| 2015 | $402 |
| 2014 | $324 |
| 2013 | $244 |
| 2012 | $317 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |